SCHEMBL1850373

SCHEMBL1850373

CC(C)(C)OC(=O)N1C[C@H](F)C[C@H]1c1nc2c(oc3ccc(Cl)cc32)c(=O)[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 14/20 0.56
CSNK2B P67870 13/20 0.56
CDC7 O00311 12/20 0.56
CSNK2A1 P68400 11/20 0.56
CSNK2A2 P19784 4/20 0.49
GSK3B P49841 2/20 0.49
DYRK1A Q13627 2/20 0.49
CIT O14578 1/20 0.49
CYP1A2 P05177 1/20 0.49
CSNK2A3 Q8NEV1 1/20 0.49
TAOK3 Q9H2K8 1/20 0.49
PIM3 Q86V86 4/20 0.44
PIM2 Q9P1W9 4/20 0.44
HCRTR1 O43613 4/20 0.39
HCRTR2 O43614 4/20 0.39
DYRK3 O43781 1/20 0.38
IGF1R P08069 1/20 0.38
CLK2 P49760 1/20 0.38
GSK3A P49840 1/20 0.38
PKN2 Q16513 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1855315 1.00 PIM1 (0.56) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1855317 1.00 PIM1 (0.56) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1855957 0.91 PIM1 (0.50) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1855956 0.91 PIM1 (0.50) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1849797 0.90 PIM1 (0.57) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1853307 0.90 PIM1 (0.57) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1852758 0.90 PIM1 (0.57) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1850649 0.89 PIM1 (0.59) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1850651 0.89 PIM1 (0.59) PIM1CSNK2BCDC7CSNK2A1CSNK2A2
SCHEMBL1852448 0.89 PIM1 (0.59) PIM1CSNK2BCDC7CSNK2A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 PIM1 1977/4885CSNK2B 350/4885CDC7 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.